Equities

Editas Medicine Inc

Editas Medicine Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)3.07
  • Today's Change-0.23 / -6.97%
  • Shares traded1.51m
  • 1 Year change-59.97%
  • Beta1.9637
Data delayed at least 15 minutes, as of Nov 12 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 16-Nov-23
  • 15-Aug-24
  • 19-Sep-24
  • 17-Oct-24
  • 07-Nov-24
Select bar for recommendation details.
Recommendations07-Nov-24
Buy4
Outperform6
Hold9
Sell0
Strong Sell0

Share price forecast in USD

The 14 analysts offering 12 month price targets for Editas Medicine Inc have a median target of 9.00, with a high estimate of 15.00 and a low estimate of 4.00. The median estimate represents a 193.16% increase from the last price of 3.07.
High388.6%15.00
Med193.2%9.00
Low30.3%4.00

Earnings history & estimates in USD

On Nov 04, 2024, Editas Medicine Inc reported 3rd quarter 2024 losses of -0.75 per share. This result was in line with the consensus of the 18 analysts following the company and under-performed last year's 3rd quarter results by 36.36%.
The next earnings announcement is expected on Feb 26, 2025.
Average growth rate-42.90%
Editas Medicine Inc reported annual 2023 losses of -2.02 per share on Feb 28, 2024.
Average growth rate+1.66%
More ▼

Revenue history & estimates in USD

Editas Medicine, Inc. had 3rd quarter 2024 revenues of 61.00k. This missed the 2.24m consensus estimate of the 14 analysts following the company. This was 99.38% below the prior year's 3rd quarter results.
Average growth rate+196.08%
Editas Medicine, Inc. had revenues for the full year 2023 of 78.12m. This was 296.32% above the prior year's results.
Average growth rate+135.89%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.